Results 91 to 100 of about 176,899 (274)

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, EarlyView.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

Expression of monoamine transporters, nitric oxide synthase 3 and neurotrophin genes in antidepressant-stimulated astrocytes

Frontiers in Psychiatry, 2012
Background: There is increasing evidence that glial cells play a role in the pathomechanisms of mood disorders and the mode of action of antidepressant drugs.
Sarah eKittel-Schneider, Gunter eKenis, Julia eSchek, Daniel evan den Hove, Daniel evan den Hove, Jos ePrickaerts, Klaus Peter eLesch, Klaus Peter eLesch, Harry eSteinbusch, Andreas eReif   +9 more
doaj   +1 more source

NGX-4010, a capsaicin 8% patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: integrated analysis of two phase III, randomized, controlled trials [PDF]

, 2013
BACKGROUND HIV-associated distal sensory polyneuropathy (HIV-DSP) is the most frequently reported neurologic complication associated with HIV infection.
Brew, Bruce J, Brown, Stephen, Fisher, Martin, Larbalestier, Nicholas, Moyle, Graeme, Orkin, Chloe, Schifitto, Giovanni, Simpson, David M, Tobias, Jeffrey K, Vanhove, Geertrui F   +9 more
core   +1 more source

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Epigenetic mechanisms and therapeutic innovations in chronic pain‐associated neuropsychiatric co‐morbidities

British Journal of Pharmacology, EarlyView.
Abstract Chronic pain, marked by nociceptive sensitization and maladaptive neuroplasticity, affects 30% of the global population with escalating socioeconomic burdens. Epidemiological data show a 2‐3‐fold increase in neuropsychiatric co‐morbidities among individuals with chronic pain, where epigenetic dysregulation serves as a key mechanism linking ...
Kai Zhang, Sijia Zhu, Na Xing, Zhen Zhou, Jiayi Chen, Tianen Si, Mingrui Li, Lin Jia, Yousef Rastegar‐Kashkooli, Tom J. Wang, Wei Zhu, Jing Li, Chao Jiang, Junmin Wang, Moxin Wu, Xiaoping Yin, Weidong Zang, Jian Wang, Songxue Su   +18 more
wiley   +1 more source

Late-life depression : issues for the general practitioner [PDF]

, 2018
Late-life depression (LLD) is both a prevalent and life-threatening disorder, affecting up to 13.3% of the elderly population. LLD can be difficult to identify because patients mainly consult their general practitioner (GP) for somatic complaints ...
Declercq, Tom, Lemey, Lieve, Petrovic, Mirko, Tandt, Hannelore, Van Damme, Axel   +4 more
core   +1 more source

Novel therapeutic targets for chronic visceral pain in gastrointestinal disorders

British Journal of Pharmacology, EarlyView.
Chronic visceral pain imposes a major clinical challenge in gastroenterology and beyond, profoundly impacting patients' quality of life. However, limited understanding of its complex, multifaceted pathophysiology, encompassing both peripheral and central mechanisms, continues to impede the development of effective management strategies.
Fleur Veldman, Christopher J. Black, Andrea Shin, Daniel Keszthelyi   +3 more
wiley   +1 more source

Experimental pharmacological research regarding some new quinazolin-4-ones derivatives [PDF]

, 2019
A series of new compounds with quinazolin-4-one structure, synthesized by the Pharmaceutical Chemistry Department of the Faculty of Pharmacy of the University of Medicine and Pharmacy “Carol Davila” Bucharest, was studied.
Bratu, Mihaela, Chiriță, Cornel, Chiriță, Ileana C, Limban, Carmen, Marineci, Cristina D, Negreș, Simona, Nuță, Diana C, Zbârcea, Cristina E, Ștefănescu, Emil   +8 more
core   +1 more source

Exploring Perimenopausal and Menopausal Women's Oral Health Perceptions and Practices in Australia—A Qualitative Study

Gerodontology, EarlyView.
ABSTRACT Objective To explore the perceptions and practices of women in peri/menopause towards oral healthcare in Australia. Background Hormonal changes associated with peri/menopause create a period where women may be more prone to developing oral health problems, which can significantly impact their quality of life.
Namitha Thomas, Kath Peters, Kate O' Reilly, Mariana S. Sousa, Ajesh George   +4 more
wiley   +1 more source